Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Laser Photocoagulation in Retinopathy of Prematurity (BUTTERFLEYE)
NCT04101721Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Aug 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of aflibercept in retinopathy of prematurity (ROP) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Proportion of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes. Started Oct 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT04101721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101721.